Apitegromab
Selective anti-latent-myostatin antibody — a more precise approach to myostatin inhibition.
Investigational compounds — read carefully
This section covers peptides at the frontier of research. Most entries are preclinical, in early or mid-stage clinical trials, or theoretical. Evidence levels are explicitly marked on every entry.
Nothing on these pages constitutes medical advice, dosing recommendations, or instructions for use. Many of these compounds are not commercially available; some are not legal for human use. Decisions about treatment require a qualified clinician.
At a glance
Scholar Rock's selective approach: bind myostatin only in its latent (inactive) state, blocking its activation rather than the mature ligand. Phase 3 in spinal muscular atrophy with positive results.
- Class
- Anti-latent-myostatin monoclonal antibody
- Sponsor
- Scholar Rock
- Stage
- Phase 3 (SMA); investigational in obesity
- Distinctive feature
- Selective for latent (pro-form) myostatin
What it is
Apitegromab is a monoclonal antibody designed to selectively bind the inactive precursor ("latent") form of myostatin, preventing its activation into mature myostatin. This selectivity differentiates it from older myostatin pathway inhibitors that bind active myostatin and related ligands non-selectively.
Current research status
Apitegromab completed the Phase 3 SAPPHIRE trial in non-ambulatory patients with spinal muscular atrophy (SMA) with positive results, and Scholar Rock has filed for FDA approval. Beyond SMA, the company has signaled interest in obesity and other muscle-preservation indications, though the priority near-term focus has been the SMA approval pathway.
Mechanistic rationale
Myostatin is synthesized as an inactive precursor that requires proteolytic activation to bind ActRIIB and suppress muscle growth. By targeting the precursor specifically, apitegromab inhibits myostatin activation rather than binding the active ligand — a strategy designed to avoid off-target effects on related TGF-β family members like activin A, GDF11, and BMP9.
Available evidence
SAPPHIRE Phase 3 trial (2024 readout) — Apitegromab improved motor function (Hammersmith Functional Motor Scale-Expanded scores) in non-ambulatory SMA patients on background nusinersen or risdiplam therapy.[1]
TOPAZ Phase 2 (Crawford et al.) — Earlier Phase 2 data established the mechanistic basis and supported Phase 3 advancement.[2]
Why it's interesting
The selectivity argument is conceptually clean. Earlier myostatin pathway inhibitors have struggled with off-target effects on activin A and other related ligands — sotatercept's pivot away from muscle preservation is partly that story. Apitegromab's design avoids those off-target pathways. If the SMA approval reads through to broader muscle-preservation indications, it would represent a fundamentally different approach to the problem than bimagrumab's broader receptor blockade.
Limitations & risks
Translation from SMA to obesity-related muscle preservation is not automatic. The patient populations, baseline muscle physiology, and concurrent therapies differ substantially. The Phase 3 SMA data is in patients with a specific motor-neuron disease; whether selective latent-myostatin inhibition produces meaningful muscle preservation in healthy obese adults losing weight on GLP-1s is a separate empirical question that hasn't been answered.
Community discussion notes
Less discussed in fitness communities than bimagrumab, partly because the SMA indication is medically focused. The pharmacologic question — whether selectivity for latent myostatin is the right target — is one of the more interesting open scientific questions in the muscle-preservation space.
The takeaway
Apitegromab is the most clinically advanced selective-myostatin program in development. The SMA approval (if granted) would provide a major precedent for the molecule and for the broader concept of latent-myostatin-specific targeting. Whether it translates to broader muscle-preservation use cases is a question for trials still ahead.
References
- Scholar Rock. SAPPHIRE Phase 3 trial of apitegromab in spinal muscular atrophy: positive topline results. (Press release / regulatory filing, 2024.) https://pubmed.ncbi.nlm.nih.gov/?term=apitegromab
- Crawford TO, et al. Apitegromab in patients with type 2 or 3 spinal muscular atrophy: TOPAZ phase 2 trial. Muscle Nerve. 2024;69(1):18-25. https://pubmed.ncbi.nlm.nih.gov/37937327/